Related Experiment Video
Updated: Oct 17, 2025
10:13
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
2.3K
Denosumab Does Not Decrease Local Recurrence in Giant Cell Tumor of Bone Treated With En Bloc Resection.
Orthopedics
|October 7, 2021
Summary
Preoperative denosumab did not reduce local recurrence risk in giant cell tumor of bone patients undergoing en bloc resection. The duration of denosumab treatment also showed no association with recurrence rates.
Area of Science:
- Orthopedic Oncology
- Bone Tumors
- Pharmacological Treatments
Background:
- Giant cell tumor of bone (GCTB) is an aggressive bone tumor.
- En bloc resection is a standard surgical treatment for GCTB.
- Local recurrence is a significant concern after GCTB resection.
Purpose of the Study:
- To evaluate if preoperative denosumab reduces local recurrence in GCTB patients treated with en bloc resection.
- To determine the optimal duration of preoperative denosumab regarding local recurrence risk.
Main Methods:
- Systematic analysis of existing studies.
- Meta-analysis of local recurrence rates in patients with and without preoperative denosumab.
- Meta-regression to assess the association between denosumab duration and recurrence.
Main Results:
- Denosumab did not significantly decrease the risk of local recurrence (OR=0.76, P=.67).
- Local recurrence rates were 3.6% with denosumab vs. 14.2% without.
- No association found between denosumab duration and local recurrence risk (P=.83).
Conclusions:
- Preoperative denosumab does not appear to reduce local recurrence risk after en bloc resection for GCTB.
- A 3-month denosumab course is adequate for bone hardening without increasing complications.
- Further research may be needed to clarify denosumab's role in GCTB management.
